Monstrous Takeaways from Monster’s $175 Million Trademark Arbitration Victory
Client Alert | 2 min read | 07.21.22
Monster has matched the size of its energy drinks with its recent arbitration award—securing a staggering $175 million in a trademark dispute heard by arbitrator Bruce Isaacs. While many contractual conflicts are resolved through arbitration, few trademark infringement cases land in arbitration and even fewer involve such a high monetary award.
The dispute arose between two beverage companies, Orange Bang Inc. and Vital Pharmaceuticals Inc., who had maintained a co-existence agreement where Vital would only use the name “Bang” for drinks with creatine. Monster, which later learned about that agreement, joined and proceeded to litigate the matter in exchange for half of the recovery. After the California-based arbitrator, Bruce Isaacs, rendered his opinion in April, respective motions to confirm and vacate the arbitration award ended in the favor of Orange Bang and Monster. U.S. District Judge Dale S. Fischer asserted that Isaacs’ opinion “grapples in good faith with the various conflicts in the case” and that Vital’s arguments fell “far short of the standard for vacating an arbitration award.”
Between Monster’s “intervention” in the dispute and the nine-digit number at the end, the takeaways for those considering arbitration are large. First, the outcome shows the importance of the arbitrator—selecting a specific arbitrator will not just position certain parties better, but can also affect the size of the award. Especially given the great scope of discretion with respect to remedies under the Lanham Act, companies pursuing trademark litigation may want to broaden their horizons with arbitration. Beyond the dollar signs themselves, Monster’s conduct in this matter invites some thought with respect to dispute resolution. Perhaps, sticking one’s nose in other people’s business can pay off. In 2019, Monster entered into an agreement with Orange Bang that assigned parts of the co-existence agreement that Orange Bang entered with Vital in 2010. This maneuver enabled Monster to then join as a co-claimant and litigate the case. In addition to securing a significant payout, Monster may have fulfilled other corporate agendas as another, albeit larger, player in the beverage industry alongside the initial parties.
While Monster’s maneuver could be seen as a gamble that paid off, it is difficult to deny the intentionality of the company’s actions. The idea of joining and co-opting disputes involving industry rivals can hold as much promise as risk. Competitors should take note of this decision because it demonstrates that a competitor with an agenda may involve itself with a third party in arbitration or litigation when it meets that company’s overall strategy in the marketplace. Arbitration, as all of this has shown, could prove to be an effective way of mitigating that risk and maximizing the rewards.
Contacts
Insights
Client Alert | 5 min read | 08.21.26
FTC Proposes Enforcement Policy Statement on Personalized Pricing: What Businesses Need to Know
On August 19, 2026, the Federal Trade Commission (FTC) announced a proposed Enforcement Policy Statement on personalized pricing — the practice of companies using consumers’ personal data to set individualized prices, discounts, coupons, or other incentives. The proposed statement, which is open for public comment for 30 days following publication in the Federal Register, marks a major step up in the FTC’s focus on data-driven pricing strategies and puts businesses across industries on notice that undisclosed or inadequately disclosed personalized pricing will not be tolerated. Importantly, while the proposed statement is not a binding legal requirement and does not create new legal obligations, it serves as an enforcement warning that the FTC is prepared to use its existing enforcement authority under Section 5 of the FTC Act (Section 5) and is also a potential harbinger of rulemaking. Businesses that engage in — or are considering — personalized pricing should carefully assess their disclosure practices and data collection procedures against the standards articulated in this statement.
Client Alert | 7 min read | 08.19.26
CMS’s Final Rule Bans Federal Medicaid Funding for Youth Gender-Affirming Care
Client Alert | 2 min read | 08.19.26

